<?xml version="1.0" encoding="UTF-8"?>
<p>All eight failures in SHARED‐2 participants represented relapses (i.e., an unquantifiable viral load at the end of treatment followed by a quantifiable viral load at week 24). SHARED‐2 participants with subtype 4r had a lower SVR12 rate compared to those without subtype 4r (50% vs. 91%; 
 <italic>P</italic> = 0.027). All 8 participants who failed to achieve SVR12 had adherence levels of over 95%, based on pill count.
</p>
